Researchers have said psychedelic-assisted psychotherapy may hold promise for both improving health and saving costs, but that the current therapeutic approach is poorly targeted.
New results have demonstrated treating major depressive disorder (MDD) with psilocybin-assisted psychotherapy is effective for up to a year in some patients.
The philanthropic arm of atai Life Sciences, atai Impact, has donated $500,000 to The Multidisciplinary Association for Psychedelics (MAPS) for multi-year support of MAPS’ ongoing initiatives,...
Launching its first European therapy centre in the Netherlands in early 2021, Field Trip Health is providing psychedelic healing experiences using truffles.
The training of psychotherapists has begun for a clinical trial that will examine 5-MeO-DMT assisted psychotherapy in treatment-resistant depression (TRD).
Mydecine has signed a Letter of Intent (LOI) with The Newly Institute to provide psychedelic-assisted psychotherapy to patients for Health Canada’s Special Access Program.
Results from a new study have demonstrated that 10mg or 25mg doses of psilocybin have no long- or short-term detrimental effects in healthy individuals.
UK company Clerkenwell Health is working to develop a gold standard in the delivery of psychedelic care.
Mydecine Innovations Group recently signed a five-year agreement with Johns Hopkins University School of Medicine that will advance research on novel psychedelic therapy.
Co-founder and CEO Anthony Tennyson spoke to Psychedelic Health about Awakn’s mission to transform mental health and addiction care through psychedelics.